Silence's polycythemia vera drug, called divesiran, could compete with a Takeda drug nearing approval called rusfertide.
An experimental medicine from Silence Therapeutics stabilized red blood cell levels in patients with a rare blood cancer in a new trial — a result that could position it to compete with a drug from Takeda Pharmaceuticals that is nearing approval.
The... [393 chars]